Xue Xinni, Li Zhiwei, Zhao Jiahui, Zhao Ziyi, Li Zhihang, Li Yong, Liu Yawen, He Huan
NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, 130021, Jilin, China.
Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, Jilin, China.
Discov Oncol. 2025 Jan 20;16(1):61. doi: 10.1007/s12672-025-01783-1.
Activating protein 1 (AP-1) is a transcription factor composed of several protein families, Jun proteins and Fos proteins are the components of AP-1. AP-1 is involved in various cellular processes, such as proliferation, differentiation, apoptosis and inflammation. For tumor cells, AP-1 is considered to be a driver whose activity is associated with dysfunction and the onset, development, invasion, and migration of cancer. In addition, AP-1 has been reported to be involved in the drug resistance and radiation resistance of tumor cells during the treatment process. Therefore, AP-1 is a potential target for cancer therapy. At present, a number of inhibitors targeting AP-1 have been developed and have shown certain anti-cancer effects. However, due to the complex structure and function of AP-1, different structures of AP-1 show different effects in different tumor cells, and more studies are needed to reveal its mechanism of action. This article introduces the relationship between AP-1 and tumor development, summarize the current studies and developments of AP-1 related drugs, and provide the future development values of AP-1.
活化蛋白1（AP-1）是一种由多个蛋白质家族组成的转录因子，Jun蛋白和Fos蛋白是AP-1的组成成分。AP-1参与多种细胞过程，如增殖、分化、凋亡和炎症。对于肿瘤细胞，AP-1被认为是一个驱动因子，其活性与癌症的功能障碍以及发生、发展、侵袭和迁移相关。此外，据报道AP-1在治疗过程中参与肿瘤细胞的耐药性和辐射抗性。因此，AP-1是癌症治疗的一个潜在靶点。目前，已经开发出多种靶向AP-1的抑制剂，并显示出一定的抗癌效果。然而，由于AP-1的结构和功能复杂，AP-1的不同结构在不同肿瘤细胞中表现出不同的作用，需要更多的研究来揭示其作用机制。本文介绍了AP-1与肿瘤发展的关系，总结了AP-1相关药物的当前研究和进展，并提供了AP-1的未来发展价值。
